These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 17454614)

  • 1. A new allelic discrimination assay using locked nucleic acid-modified nucleotides (LNA) probes for detection of JAK2 V617F mutation.
    Marková J; Průková D; Volková Z; Schwarz J
    Leuk Lymphoma; 2007 Mar; 48(3):636-9. PubMed ID: 17454614
    [No Abstract]   [Full Text] [Related]  

  • 2. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
    Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
    Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JAK2-V617F mutation in Moroccan patients with myeloproliferative disorders: contribution, diagnosis and therapeutic prospects.
    Benmoussa A; Dehbi H; Fehri S; Quessar A; Nadifi S
    Pathol Biol (Paris); 2011 Aug; 59(4):e89-92. PubMed ID: 19939582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid identification of heterozygous or homozygous JAK2(V617F) mutations in myeloproliferative neoplasms using melting curve analysis.
    Ho CL; Wu YY; Hung HM; Chang PY; Kao WY; Chen YC; Chao TY
    J Formos Med Assoc; 2012 Jan; 111(1):34-40. PubMed ID: 22333011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. De novo CSF3R mutation associated with transformation of myeloproliferative neoplasm to atypical CML.
    Bartels S; Lehmann U; Büsche G; Schlue J; Hussein K; Debatin D; Karcher A; Andrulis M; Schirmacher P; Kreipe H
    Ann Hematol; 2015 Jul; 94(7):1255-6. PubMed ID: 25865944
    [No Abstract]   [Full Text] [Related]  

  • 6. Detection of acquired Janus kinase 2 V617F mutation in myeloproliferative disorders by fluorescence melting curve analysis.
    Reading NS; Lim MS; Elenitoba-Johnson KS
    Mol Diagn Ther; 2006; 10(5):311-7. PubMed ID: 17022694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of JAK2 V617F burden quantitation by two different quantitative-polymerase chain reaction methods.
    Le Bars H; Boulland ML; Bareau B; Grosbois B; Corolleur M; Lamy T; Fardel O
    Int J Lab Hematol; 2010 Aug; 32(4):458-60. PubMed ID: 20331762
    [No Abstract]   [Full Text] [Related]  

  • 8. Concomitant BCR-ABL1 translocation and JAK2(V617F) mutation in three patients with myeloproliferative neoplasms.
    Hummel JM; Kletecka MC; Sanks JK; Chiselite MD; Roulston D; Smith LB; Czuchlewski DR; Elenitoba-Johnson KS; Lim MS
    Diagn Mol Pathol; 2012 Sep; 21(3):176-83. PubMed ID: 22847163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders.
    Rumi E; Passamonti F; Pietra D; Della Porta MG; Arcaini L; Boggi S; Elena C; Boveri E; Pascutto C; Lazzarino M; Cazzola M
    Cancer; 2006 Nov; 107(9):2206-11. PubMed ID: 16998940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chip-based digital polymerase chain reaction technology is useful for monitoring the JAK2 V617F allele burden in Philadelphia-negative myeloproliferative neoplasms.
    Furuya D; Moriai M; Murai R; Moriai R; Koizumi Y; Endo T; Asanuma K; Yanagihara N; Takahashi S
    Int J Lab Hematol; 2019 Oct; 41(5):e113-e116. PubMed ID: 30903743
    [No Abstract]   [Full Text] [Related]  

  • 11. What is the role of JAK2(V617F) mutation in leukemic transformation of myeloproliferative neoplasms?
    Lopes da Silva R; Ribeiro P; Lourenço A; Santos SC; Santos M; Costa I; de Sousa AB
    Lab Hematol; 2011 Mar; 17(1):12-6. PubMed ID: 21421540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The incidence of JAK2 V617F mutation in bcr/abl-negative chronic myeloproliferative disorders: assessment by two different detection methods.
    Lucia E; Martino B; Mammi C; Vigna E; Mazzone C; Gentile M; Qualtieri G; Bisconte MG; Naccarato M; Gentile C; Laganà C; Romeo F; Neri A; Nobile F; Morabito F
    Leuk Lymphoma; 2008 Oct; 49(10):1907-15. PubMed ID: 18720212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical performance of JAK2 V617F mutation detection assays in a molecular diagnostics laboratory: evaluation of screening and quantitation methods.
    Cankovic M; Whiteley L; Hawley RC; Zarbo RJ; Chitale D
    Am J Clin Pathol; 2009 Nov; 132(5):713-21. PubMed ID: 19846812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Advance of study on JAK2 V617F in myeloproliferative disorders -- review].
    Xu YY; Li HM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Feb; 17(1):238-42. PubMed ID: 19236788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A novel modi cation of real-time AS-qPCR by using locked nucleic acid-modified oligonucleotide probe as wild type allele amplification blockers for quantitative detection of the JAK2 V617F mutation].
    Shao DH; Liang GW; He ML; Cao QY
    Zhonghua Xue Ye Xue Za Zhi; 2013 May; 34(5):421-5. PubMed ID: 23688754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Locked nucleic acid probes for enhanced detection of FLT3 D835/I836, JAK2 V617F and NPM1 mutations.
    Warshawsky I; Mularo F
    J Clin Pathol; 2011 Oct; 64(10):905-10. PubMed ID: 21666141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. No evidence for amplification of V617F JAK2 in myeloproliferative disorders.
    Jones AV; Bunyan DJ; Cross NC
    Leukemia; 2007 Dec; 21(12):2561-3. PubMed ID: 17611555
    [No Abstract]   [Full Text] [Related]  

  • 18. Diagnostic refinement of chronic myeloproliferative disorders and thrombocytoses of unknown origin by multiple RT-PCR and capillary electrophoresis of BCR-ABL rearrangements and JAK2 (V617F) mutation.
    Ammatuna E; Ottone T; Zaza S; Lavorgna S; Grillo R; Curzi P; Panetta P; Federici G; Amadori S; Lo-Coco F
    Ann Hematol; 2007 May; 86(5):355-61. PubMed ID: 17285276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JAK2 46/1 haplotype is associated with JAK2 V617F--positive myeloproliferative neoplasms in Brazilian patients.
    Macedo LC; Santos BC; Pagliarini-e-Silva S; Pagnano KB; Rodrigues C; Quintero FC; Ferreira ME; Baraldi EC; Ambrosio-Albuquerque EP; Sell AM; Visentainer JE
    Int J Lab Hematol; 2015 Oct; 37(5):654-60. PubMed ID: 25959311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concomitant detection of BCR-ABL translocation and JAK2 V617F mutation in five patients with myeloproliferative neoplasm at diagnosis.
    Cappetta M; Pérez V; Zubillaga MN; Elizondo V; Manrique G; Prosper I; Boschi S; Bonomi R; Pomoli S; Díaz L; Martínez L; Uriarte MR
    Int J Lab Hematol; 2013 Feb; 35(1):e4-5. PubMed ID: 23062104
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.